JP2024510502A5 - - Google Patents

Info

Publication number
JP2024510502A5
JP2024510502A5 JP2023557351A JP2023557351A JP2024510502A5 JP 2024510502 A5 JP2024510502 A5 JP 2024510502A5 JP 2023557351 A JP2023557351 A JP 2023557351A JP 2023557351 A JP2023557351 A JP 2023557351A JP 2024510502 A5 JP2024510502 A5 JP 2024510502A5
Authority
JP
Japan
Prior art keywords
compound according
independently selected
sulfur
nitrogen
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020474 external-priority patent/WO2022197755A1/en
Publication of JP2024510502A publication Critical patent/JP2024510502A/ja
Publication of JP2024510502A5 publication Critical patent/JP2024510502A5/ja
Pending legal-status Critical Current

Links

JP2023557351A 2021-03-17 2022-03-16 血漿カリクレインのイミダゾピリジニル阻害剤 Pending JP2024510502A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162494P 2021-03-17 2021-03-17
US63/162,494 2021-03-17
PCT/US2022/020474 WO2022197755A1 (en) 2021-03-17 2022-03-16 Imidazopyridinyl inhibitors of plasma kallikrein

Publications (2)

Publication Number Publication Date
JP2024510502A JP2024510502A (ja) 2024-03-07
JP2024510502A5 true JP2024510502A5 (cg-RX-API-DMAC10.html) 2025-03-21

Family

ID=81325446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557351A Pending JP2024510502A (ja) 2021-03-17 2022-03-16 血漿カリクレインのイミダゾピリジニル阻害剤

Country Status (4)

Country Link
EP (1) EP4308227A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024510502A (cg-RX-API-DMAC10.html)
CN (1) CN117396473A (cg-RX-API-DMAC10.html)
WO (1) WO2022197755A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112135825A (zh) 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
CN114728962B (zh) 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
CA2760778A1 (en) * 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
US8927559B2 (en) * 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
US9624170B2 (en) * 2013-12-26 2017-04-18 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors
DK3169671T3 (da) * 2014-07-17 2019-09-23 Sunshine Lake Pharma Co Ltd 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
US20240382482A1 (en) * 2021-03-17 2024-11-21 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors
EP4585265A3 (en) * 2021-03-17 2025-10-15 Takeda Pharmaceutical Company Limited Heteroaryl inhibitors of plasma kallikrein

Similar Documents

Publication Publication Date Title
DE69108138T2 (de) Imidazopyridinderivate und ihre Verwendung.
KR101678255B1 (ko) 치환 아미드 화합물
JP2022548696A5 (cg-RX-API-DMAC10.html)
JP2024516073A5 (cg-RX-API-DMAC10.html)
JP5596680B2 (ja) 経口抗がん製剤
AU2017254523A1 (en) Compounds and compositions for treating conditions associated with NLRP activity
JP5819954B2 (ja) 抗炎症剤、免疫調節剤及び抗増殖剤としての化合物の新規カルシウム塩
JP2024510503A5 (cg-RX-API-DMAC10.html)
JP2021120401A (ja) 水溶性プロドラッグ
AU596969B2 (en) 2,5 - diaryl tetrahydrofurans and 2-aryl-5-cyclo tetrahydrofurans and analogs thereof as paf antogonists
CN113024422B (zh) 丁苯酞开环化合物、药物化合物以及它们的制备方法、组合物和应用
JP2009533398A (ja) アルテミシニン誘導体の二量体、この調製およびこの治療上の使用
CN120418236A (zh) 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
JP2024510504A5 (cg-RX-API-DMAC10.html)
JP2021512132A (ja) 置換イミダゾールカルボン酸エステル系誘導体およびその使用
JP2024512497A5 (cg-RX-API-DMAC10.html)
RU2007106037A (ru) Производные пиримидисульфонамида в качестве модуляторов рецепторов хемокинов
JP2025527291A5 (cg-RX-API-DMAC10.html)
KR20070106981A (ko) 종양괴사인자-알파의 저해제인 접합된 트리사이클릭 화합물
KR20060109871A (ko) 증식성 질병 치료용 알파, 베타-불포화 설폭시드
KR20100014974A (ko) 아미드 화합물 및 이의 항종양제로서의 용도
LV10712B (en) 2-ciano-3-hydroxypropene amides
CN117586204A (zh) 异硒唑酮类化合物、其合成方法及用途
WO2005061492A1 (ja) 含窒素複素環化合物およびそれらを有効成分とする薬剤
JPH0356488A (ja) 抗アテローム性動脈硬化症アザフロクロモン